Sartorius Stedim Biotech S.A. provided consolidated sales guidance for the year 2019. For the year, the company expects continued profitable growth in 2019. Consolidated sales revenue is projected to grow by about 7% to 11%. This forecast reflects the changes to the sales agreement with the Lonza group for cell culture media. Without these changes, sales growth would probably be approximately 3 percentage points higher.